乳癌に対する分子標的治療の進歩 (第77回東京女子医科大学学会総会 シンポジウム「生物学的製剤を用いた分子標的治療の進歩」)  [in Japanese] The Progress of Molecular Targeted Therapies with Biologics against Breast Cancer  [in Japanese]

Access this Article

Search this Article

Author(s)

    • 神尾 孝子 Kamio Takako
    • 東京女子医科大学医学部外科学(第二) Department of Surgery II, Tokyo Women's Medical University School of Medicine
    • 亀岡 信悟 Kameoka Shingo
    • 東京女子医科大学医学部外科学(第二) Department of Surgery II, Tokyo Women's Medical University School of Medicine

Abstract

The 77th Annual Meeting of the Society of Tokyo Women's Medical University第77回東京女子医科大学学会総会  平成23年10月8日(土) 東京女子医科大学 弥生記念講堂

In recent years, analyses regarding the mechanisms that control the proliferation/survival of tumor cells and amplification/overexpression of molecules in tumor cells are now underway, making possible construction of new treatment strategies with these as the target. ,In the field of breast cancer treatment, trastuzumab, which is a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), was clinically introduced in June, 2001. This agent demonstrated a significant improvement in the prognosis of HER2-positive breast cancer patients and expansion of its adaptation to postoperative adjuvant therapy and preoperative therapy has been attempted, beginning with the treatment against advanced/recurring breast cancers. Moreover, research regarding concomitant drugs has advanced, with many clinical trials currently in progress.,Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), which is an angiogenic factor observed as having additive therapeutic effects on advanced/recurring breast cancers in combined use with chemotherapy. Its application for the treatment of breast cancer in Japan was approved in September, 2011 followed by colon cancer and lung cancer, making clinical applications possible. ,In addition, many clinical trials are being carried out with the invention of the monoclonal antibody pertuzumab, which inhibits heterodimer formation of HER2 with HER1 or HER3, trastuzumab emtansine (T-DM1), which is an antibody-drug conjugate (ADC), etc., and in the future the realization of "personalized medicine" is thus hoped for in the treatment of breast cancer.

Journal

  • Journal of Tokyo Women's Medical College

    Journal of Tokyo Women's Medical College 82(2), 75-79, 2012-04

    Tokyo Women's Medical University

Codes

  • NII Article ID (NAID)
    110009004321
  • NII NACSIS-CAT ID (NCID)
    AN00161368
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • Journal Type
    大学紀要
  • ISSN
    0040-9022
  • NDL Article ID
    023773798
  • NDL Call No.
    Z19-400
  • Data Source
    NDL  NII-ELS  IR 
Page Top